SC
APLS

Sessa Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Sessa Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-149,000
Closed -$7.7M – 39
2022
Q4 		$7.7M Hold
149,000
– – 0.47% 21
2022
Q3 		$10.2M Hold
149,000
– – 0.73% 20
2022
Q2 		$6.74M Hold
149,000
– – 0.37% 22
2022
Q1 		$7.57M Buy
+149,000
New +$6.58M 0.36% 27

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sessa Capital's APLS Position: Q1 2023 in Review

Sessa Capital sold out of Apellis Pharmaceuticals (APLS) in Q1 2023, closing a stake of 149,000 shares — an estimated $7.7M sold.

Sessa Capital first reported a position in APLS in Q1 2022 and held it in 4 quarters. The position peaked at $10.2M in Q3 2022. 281 funds tracked by Wall St. Rank hold APLS as of Q1 2023.

  • Sessa Capital reported no remaining Apellis Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Sessa Capital sold 149,000 Apellis Pharmaceuticals shares in Q1 2023, an estimated $7.7M.
  • Sessa Capital first reported a position in Apellis Pharmaceuticals in Q1 2022 and held it in 4 quarters.
  • Sessa Capital's Apellis Pharmaceuticals position peaked at $10.2M in Q3 2022.
  • 281 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2023.

Based on Sessa Capital's 13F filing for Q1 2023, filed 15 May 2023.